CureVac Sues Moderna Over 8 mRNA Patents, Deepening Vaccine Royalty Battle

German biotech firm CureVac has sued Moderna in Delaware federal court, alleging that the U.S. company's Spikevax COVID-19 vaccine infringes on eight of its patents for messenger RNA technology, escalating the high-stakes legal war over the profits from the pandemic's most successful medical products.

"Moderna copied its technology for stabilizing fragile mRNA to use in vaccines," CureVac said in the lawsuit, requesting royalties from Moderna’s Spikevax sales in damages. A spokesperson for Moderna (NASDAQ: MRNA) stated the company was aware of the lawsuit and will defend itself against the allegations.

The lawsuit, filed on April 24, is the latest in a series of patent disputes among the key players in the COVID-19 vaccine space. Germany-based BioNTech, which partnered with Pfizer on the competing Comirnaty vaccine, acquired CureVac last year and filed its own patent suit against Moderna in February. Moderna, in turn, sued Pfizer and BioNTech in 2022 over Comirnaty, in a case that is still ongoing.

This wave of litigation, involving giants like GlaxoSmithKline and Bayer, highlights the immense financial stakes tied to mRNA technology. A successful suit could secure a significant revenue stream for CureVac from Moderna's tens of billions in Spikevax sales, while a loss would reinforce Moderna's intellectual property position and potentially deter further challenges.

A Widening Web of Litigation

The dispute between CureVac and Moderna is not an isolated event but part of a broader, industry-wide battle for compensation over the foundational technologies that enabled the rapid development of COVID-19 vaccines. These vaccines have generated tens of billions of dollars in revenue, and companies that hold key patents are now seeking a share of the profits.

The legal landscape is complex and interconnected. BioNTech's acquisition of CureVac consolidates the front against Moderna, creating a two-pronged legal assault. While Moderna is defending itself against these claims, it is simultaneously pursuing its own infringement case against Pfizer and BioNTech, creating a complex web of accusations and counter-accusations that could take years to resolve.

Broader Implications for Pharma Patents

The situation mirrors other high-stakes patent disputes in the pharmaceutical industry, such as the ongoing case between Amarin Pharma and Hikma Pharmaceuticals over a generic heart medication. As detailed in a recent SCOTUSblog analysis, these cases often hinge on complex questions of "induced infringement," where a company is held liable for how its product is used by others.

In the case of mRNA vaccines, the core issue is who owns the fundamental intellectual property for stabilizing and delivering the mRNA. The outcome of CureVac's lawsuit, along with the other related cases, could set a major precedent for IP rights in the rapidly evolving field of mRNA therapeutics, potentially affecting the development and commercialization of future vaccines and treatments. For investors, the legal overhang adds a layer of uncertainty to Moderna's future earnings, with the potential for significant royalty payments or damages impacting its valuation.

This article is for informational purposes only and does not constitute investment advice.